Spearheading a transformation

Dr. Dan Hashimshony is an entrepreneurial leader and business executive with extensive experience in venture-backed companies in highly regulated fields. Dan has a strong background in science and engineering, in biomedical companies. Prior to joining Epitomee, Dan was the founding CEO of Dune Medical Devices, a surgical oncology company (Acquired by Dilon Technologies). He led Dune since its inception through multiple financing rounds, product development stages, regulatory approval, and commercialization. Prior to that Dan was with X-Technologies (acquired by Guidant 2003) and Sela Semiconductor (acquired by Camtek). Dan holds a Ph.D. in Physics, from the Racah Institute of Physics at the Hebrew University, Jerusalem.

An inventor, active entrepreneur and investor in the field of medical devices and medical technology,
Until July 2017 Shimon was the chairman of Syneron Medical Ltd. (Nasdaq ELOS) which he co-founded in 2001, until it was acquired by APAX partners.

Shimon is the chairman and co-founder of Alon Medtech, Sofwave, Rapid Medical, Theranica, RealView. Shimon was a co-founder, chairman and CEO of ColorChip from 2001 to 2003; Was a co-founder of Ventor Medical Technologies and its Chairman until it was acquired by Medtronic in 2009 for $325M.

Shimon was the founder, chairman and CEO of Lumenis (former ESC) from its inception in 1992 until 1999. He took the company public on Nasdaq in 1996 and raised more than $250M in 3 public offerings, the company reached a valuation of more than $1B returning to its investors more than X120 on their investment in the company.

Shimon is the inventor of IPL (Intense Pulsed Light) technology which he brought to market in 1994 in ESC and is the most popular non-invasive energy based technology for a broad range of non-invasive medical aesthetic applications.

Shimon holds a BSc in physics from the Technion – Israeli Institute of Technology and a Ph.D. in physics from the University of California at Irvine. He is the author of more than 60 US registered patents and a few hundred international patents and published more than 50 papers in leading refereed journals and conferences.

Maya possesses over 10 years of experience in various financial roles, including extensive experience in financing and accounting, primarily in public companies with international focus. Prior to Epitomee medical Maya was the financial controller in a public company trade in the TLV stock exchange and as a senior auditor in KPMG.
Maya is an Israeli CPA and holds a bachelor’s degree in Economics & Accounting from the Bar Ilan University.

Gil brings more than 20 years of experience in R&D, leadership roles in various fields, including Medical devices, Bio-tech, and Clean-tech. As the VP R&D of the company he brings a vast scientific and managerial experience including in product development, data analysis, IP, and the development of Manufacturing and QC methods. Before joining Epitomee in 2018, Gil was Chief Scientific Officer in Dune Medical Device (Acquired by Dilon Technologies) Gil holds a B.Sc. in Physics and Mathematics and Ph.D. in Physics from the Hebrew University, Jerusalem with a post doc in Biology.

Yael is an executive in the pharma and medical device Industry with a demonstrated ability for excellence and valuable results in clinical, medical and regulatory affairs. In Epitomee, Yael is responsible for Clinical Affairs, leading the clinical development of the company products and executes the company’s entire clinical studies. Before joining Epitomee in 2020 Yael effectively directed and managed professional international teams and played a leading role in obtaining a global marketing authorization for Teva’s second ethical drug, Azilect®,. She executed the company’s entire clinical studies’ program for the New Drug Application and lead the clinical-regulation interactions with the FDA and EMEA. Yael was COO at TransPharma Medical, Ltd., and CEO at Lacrima Medical, Ltd., , Yael established and has managed the medical and clinical department at Cellect Biotechnology, an innovative cell therapy technology in the area of Oncology and Immunology. Yael holds Ph.D from the Hebrew university, MBA from the Technion and was a visiting fellow in NHLBI (NIH institute).

Gal is an industry veteran with more than 25 years of experience in leading product development, engineering and operational teams in early-stage medical device companies and mature international public corporations. Products sold globally worth hundreds of millions of dollars annually, were developed and manufactured under Gal’s responsibility. Before joining Epitomee in 2020, Gal was the COO & GM of Dune Medical Devices in Israel (Acquired by Dilon Technologies). Prior to that, he was head of R&D at Lumenis and at SHL Telemedicine. Gal holds a B.Sc. degree in mechanical engineering from Ben-Gurion University in Israel.

Dr. Ruthie Amir joined Epitomee Medical as the chief medical officer in 2018.Prior to joining Epitomee Medical Ruthie served as the director of clinical research and the head of the regulatory department of Syneron Candela from 2008 to 2017. Ruthie graduated from Ben Gurion University Medical School. From 1996-2000, she completed her post-doctoral fellowship in the Department of Human Genetic, at Baylor College of Medicine, Houston, USA where she worked on the genetic basis of Rett Syndrome. Between 2000-2003 she completed a post-doctoral fellowship in the Department of Cell Biology, Faculty of Medicine, Technion.

Safi is a veteran pharma executive with more than 20 years of experience. She brings extensive expertise in business development, product commercialization, market access, partnerships and management.

In Epitomee, Safi leads all aspects of business development activities. Prior to joining Epitomee, Safi held several executive business development positions, where she significantly contributed to the growth of companies such as Dexcel Pharma, Mapi Pharma and Chartwell Pharmaceuticals and was drug & device procurement manager of Meuhedet (3rd largest HMO). She was also a director member of the board in TASE Bio companies.

Safi holds a B.Pharm summa cum laude from The Hebrew University and an MBA from The University of Bradford.

Alon Heth is a results-driven leader with over 20 years of extensive international experience in Sales and Marketing. He has a proven track record of managing complex international sales operations for multidisciplinary systems and solutions across various sectors, including Medical Devices, Diagnostic Imaging, Robotics, and other industrial markets.
Alon brings deep expertise in developing and managing global distribution and partner networks, with a strong focus on B2B and B2C sales. He has successfully structured comprehensive marketing platforms, encompassing social and digital media strategies.
Before joining Epitomee, Alon held several senior positions as VP of Sales and Marketing, where he played a pivotal role in driving the growth of companies such as Elscint, B-Cure Laser, Human Xtensions, Netvision, and others.
Alon holds a B.A. degree in Economics and Logistics from Bar Ilan University and a Master’s degree in Management.

An inventor, active entrepreneur and investor in the field of medical devices and medical technology,
Until July 2017 Shimon was the chairman of Syneron Medical Ltd. (Nasdaq ELOS) which he co-founded in 2001, until it was acquired by APAX partners.

Shimon is the chairman and co-founder of Alon Medtech, Sofwave, Rapid Medical, Theranica, RealView. Shimon was a co-founder, chairman and CEO of ColorChip from 2001 to 2003; Was a co-founder of Ventor Medical Technologies and its Chairman until it was acquired by Medtronic in 2009 for $325M.

Shimon was the founder, chairman and CEO of Lumenis (former ESC) from its inception in 1992 until 1999. He took the company public on Nasdaq in 1996 and raised more than $250M in 3 public offerings, the company reached a valuation of more than $1B returning to its investors more than X120 on their investment in the company.

Shimon is the inventor of IPL (Intense Pulsed Light) technology which he brought to market in 1994 in ESC and is the most popular non-invasive energy based technology for a broad range of non-invasive medical aesthetic applications.

Shimon holds a BSc in physics from the Technion – Israeli Institute of Technology and a Ph.D. in physics from the University of California at Irvine. He is the author of more than 60 US registered patents and a few hundred international patents and published more than 50 papers in leading refereed journals and conferences.

Michael has over 20 years of management experience in overall financial & commercial strategy, fund raising and capital allocation, M&A transactions, investor relations, governance and risk management. Michael is a Senior executive with vast experience in investing and managing high-growth technology companies, due diligence processes, post-acquisition integration and active management and control over global subsidiaries. He has extensive knowledge of business, legal and tax aspects relating to investments, management and control of portfolio companies in different fields.

Michael serves as the Chief Financial Officer at Alon Medtech. Prior to joining Alon Medtech, Michael served as a Financial, Commercial and Operational executive in leading high-growth technology companies such as: Convergin, a provider of service broker platforms to mobile operators, acquired by Oracle; Hobart (Prof Shlomo Ben Haim’s investment group) specializing in active management of its health-care portfolio companies from startup stage through acquisition and IPOs; and Aura Investment a publicly traded investment company focused on early stage investments and active management of technology companies.

Michael has a B.A in accounting and business administration and a Master of Law (LL.M) from Bar Ilan University and is also an Israeli certified public accountant.

Yoav serves in XT Group venture capital division, which is a global holding company operating in diverse industrial fields such as Shipping, Energy, Chemicals, Automotive & Media. From 1998 to 2006, Yoav served in Yozma Venture Capital (in which the XT Group was a founding partner), initially as an analyst & later as a principal and a partner. From 2006 to-date, Yoav is serving in XT Hi-Tech, initially as a vice president & now as one of its Managing Directors. Prior to joining the XT Group, Mr. Sebba served as a project manager at one of Israel’s leading commercial banks and at a leading consulting firm. Yoav had the honor to serve in the board of directors of Cognitens (acquired by Hexagon; STO: HEXAB), Kailight Photonics (acquired by Optium; Nasdaq: OPTM), Impactia Technologies (acquired by eWave), BeamUps Technologies, Applied Spectral Imaging, Paragon Communications, Pegasus Technologies, Cognifit, Tevet (acquired by NanoMetrics; Nasdaq: NANO), CommonSense, KiloLambda, HyWire, NanoPass, IntraTech, PainReform and NextNine (acquired by Honeywell). Yoav is currently honored to serve in the board of directors of ZIM Integrated Shipping, Phytech, Sofwave, Healthy.io, Cymbio, & Vessle. Yoav holds B.Sc. in Management and Industrial Engineering, with distinction, from the Technion Institute of Technology, and an MBA from the Haifa University.

Michel is a seasoned Venture Capitalist and senior executive investing in MedTech & Biotech, expert in value building throughout the whole spectrum of tech companies development, with a track record of successful exits of over 1.5 $Bn.

Currently serves as Managing General Partner of ALIVE Israel HealthTech Fund. Serves on the BOD of Innovalve and Beyeonics.

Former advisor to CBG Ltd, a multi Billion family office based in London.

Former CEO of Hadasit Bio-Holdings (HDST), serves on the BOD of Enlivex (ENLV), Kahr Medical, Minovia, Omnix, Eximore, Xenia Ventures and VLX Incubator, served on the BOD of Meditate (acquired by Olympus), Chairman of Kahr and on the BOD of Cellcure (acquired by Biotime (LCTX)).

Former Venture Partner at Agate Medical Investments and Managing General Partner at MaC LP VC Funds, with over $100M under management, with significant exits (Lumenis, MST, Endochoice, Peptron).

Former Elron’s BD Director, managing the Medical Devices sector (Medingo, Given, Brainsgate).

Established and managed the Israel investment banking activity of ING Barings, served as VP Investment Banking at Cukierman & Co.

During the 90’s served as Israel’s Economic Consul in Boston, and as Commercial Attaché to South Korea. As Officer (Academic Reserve, Captain Res.) in the IDF Navy, managed development of advanced Naval and Aerial systems for the Navy’s elite unit.

Mr. Habib holds a BsC in Aeronautical Engineering from the Technion. He is a graduate from Israel’s foreign service economic cadet school, member of the Technion Alumni “100 Club” and graduate from the Global Executive Program on Negotiation (PON) at Harvard Law School.

Ronit brings over 25 years of global experience in alternative investments, high-tech and M&A’s.
Ronit serves as board member for Ayalon Holdings and 4 other public companies and is personally familiar with the tight knit community of entrepreneurs, scientists, investors, and government agencies- globally.
A former vice president at Battery Ventures, Ronit is a respected corporate governance and business development expert who has led investments in successful global companies.
She holds an MBA from Baruch College in New York City and PhD in Psychology.

Anya Eldan is the former VP at the Israel Innovation Authority, managing the Startup Division funding over 400 startups annually through programs such as the Seed Fund, Technological Incubators and Open Innovation Labs. Anya initiated innovation ecosystems creation programs in Bio Convergence, Alternative Proteins and Climate Tech segments, culminating in Billion-dollar Government support programs. In addition, Anya created innovation programs for periphery, metropolitan cities and the Arab Sector. Anya has over 25 years of executive experience in High Tech and Life Sciences companies, Venture Capital management and venture creation. Currently Anya serves as a Board Member, Venture Partner and leads Venture creation and innovation ecosystem programs.

Avivit Mannet Kalil, Co-CEO and Head of Research of Oppenheimer Israel, a leading foreign brokerage firm providing a full range of investment services.

Avivit graduated from Ben Gurion University of the Negev with a BA & MA in Economics and Finance and has been with Oppenheimer for more than two decades. She holds US FINRA Series 7 and Series 16 licenses in financial management and research supervisory.